$CSBR
CHAMPIONS ONCOLOGY, INC.

2014 Q1 Form 10-Q Financial Statement

#000114420414015818 Filed on March 14, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q2 2013 Q1
Revenue $3.690M $1.840M $2.917M
YoY Change 26.5% 33.33% 21.54%
Cost Of Revenue $1.010M $1.560M $1.240M
YoY Change -18.55% 1.96% -10.14%
Gross Profit $2.680M $280.0K $1.680M
YoY Change 59.52% -286.67% 64.71%
Gross Profit Margin 72.63% 15.22% 57.59%
Selling, General & Admin $2.941M $1.770M $1.803M
YoY Change 63.12% -14.49% -3.06%
% of Gross Profit 109.74% 632.14% 107.32%
Research & Development $535.0K $510.0K $592.0K
YoY Change -9.63% 34.21% -36.34%
% of Gross Profit 19.96% 182.14% 35.24%
Depreciation & Amortization $56.00K $50.00K $51.00K
YoY Change 9.8% 25.0% 155.0%
% of Gross Profit 2.09% 17.86% 3.04%
Operating Expenses $5.098M $2.270M $3.637M
YoY Change 40.17% -7.35% 30.36%
Operating Profit -$1.408M -$1.990M -$720.0K
YoY Change 95.56% -23.46% -59.32%
Interest Expense $850.0K -$50.00K -$260.0K
YoY Change -426.92% -183.33% -471.43%
% of Operating Profit
Other Income/Expense, Net $839.0K $0.00 -$265.0K
YoY Change -416.6% -100.0% 2550.0%
Pretax Income -$569.0K -$2.040M -$985.0K
YoY Change -42.23% -20.0% -42.73%
Income Tax $5.000K $0.00 $5.000K
% Of Pretax Income
Net Earnings -$574.0K -$2.050M -$990.0K
YoY Change -42.02% -19.61% -42.44%
Net Earnings / Revenue -15.56% -111.41% -33.94%
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$0.02 -$370.7K -$248.7K
COMMON SHARES
Basic Shares Outstanding 66.87M shares
Diluted Shares Outstanding 66.87M shares

Balance Sheet

Concept 2014 Q1 2013 Q2 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.810M $9.560M $10.77M
YoY Change -46.05% 102.54% 66.2%
Cash & Equivalents $5.812M $9.561M $10.77M
Short-Term Investments
Other Short-Term Assets $280.0K $320.0K $300.0K
YoY Change -6.67% 52.38% 172.73%
Inventory
Prepaid Expenses
Receivables $3.123M $500.0K $640.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.216M $10.38M $11.71M
YoY Change -21.3% 87.19% 54.28%
LONG-TERM ASSETS
Property, Plant & Equipment $421.0K $414.0K $440.0K
YoY Change -4.32% -26.07% -2.22%
Goodwill $669.0K $669.0K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $170.0K $190.0K $190.0K
YoY Change -10.53% 0.0% 26.67%
Total Long-Term Assets $1.255M $1.275M $1.300M
YoY Change -3.46% -7.54% 1.56%
TOTAL ASSETS
Total Short-Term Assets $9.216M $10.38M $11.71M
Total Long-Term Assets $1.255M $1.275M $1.300M
Total Assets $10.47M $11.65M $13.01M
YoY Change -19.52% 68.32% 46.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $937.0K $1.204M $1.100M
YoY Change -14.82% -28.16% -32.1%
Accrued Expenses $705.0K $611.0K $570.0K
YoY Change 23.68% -2.24% 67.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.737M $2.929M $2.680M
YoY Change 39.44% -15.98% -22.77%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.250M $1.050M $990.0K
YoY Change 127.27% 87.5% 59.68%
Total Long-Term Liabilities $2.250M $1.050M $990.0K
YoY Change 127.27% 87.5% 59.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.737M $2.929M $2.680M
Total Long-Term Liabilities $2.250M $1.050M $990.0K
Total Liabilities $5.985M $3.975M $3.680M
YoY Change 62.64% -1.63% -10.02%
SHAREHOLDERS EQUITY
Retained Earnings -$36.62M -$31.47M
YoY Change 25.18%
Common Stock $42.48M $23.62M
YoY Change 11.19%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.252M $1.252M
YoY Change 0.0%
Treasury Stock Shares 3.236M shares 3.236M shares
Shareholders Equity $4.486M -$9.206M $9.340M
YoY Change
Total Liabilities & Shareholders Equity $10.47M $11.65M $13.01M
YoY Change -19.52% 68.32% 46.67%

Cashflow Statement

Concept 2014 Q1 2013 Q2 2013 Q1
OPERATING ACTIVITIES
Net Income -$574.0K -$2.050M -$990.0K
YoY Change -42.02% -19.61% -42.44%
Depreciation, Depletion And Amortization $56.00K $50.00K $51.00K
YoY Change 9.8% 25.0% 155.0%
Cash From Operating Activities -$1.660M -$1.160M -$580.0K
YoY Change 186.21% -24.18% 41.46%
INVESTING ACTIVITIES
Capital Expenditures -$80.00K -$20.00K -$10.00K
YoY Change 700.0% -86.67% -95.24%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$80.00K -$20.00K -$10.00K
YoY Change 700.0% -86.67% -95.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.100M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K -60.00K 9.200M
YoY Change -100.11%
NET CHANGE
Cash From Operating Activities -1.660M -1.160M -580.0K
Cash From Investing Activities -80.00K -20.00K -10.00K
Cash From Financing Activities -10.00K -60.00K 9.200M
Net Change In Cash -1.750M -1.240M 8.610M
YoY Change -120.33% -26.19% -1488.71%
FREE CASH FLOW
Cash From Operating Activities -$1.660M -$1.160M -$580.0K
Capital Expenditures -$80.00K -$20.00K -$10.00K
Free Cash Flow -$1.580M -$1.140M -$570.0K
YoY Change 177.19% -17.39% 185.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5812000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9561000 USD
CY2014Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3123000 USD
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
281000 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
9216000 USD
CY2014Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
165000 USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
421000 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
414000 USD
CY2014Q1 us-gaap Goodwill
Goodwill
669000 USD
CY2014Q1 us-gaap Liabilities
Liabilities
5985000 USD
CY2013Q2 us-gaap Liabilities
Liabilities
3975000 USD
CY2013Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
500000 USD
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
315000 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
10376000 USD
CY2013Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
192000 USD
CY2013Q2 us-gaap Goodwill
Goodwill
669000 USD
CY2013Q2 us-gaap Assets
Assets
11651000 USD
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1204000 USD
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
611000 USD
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1114000 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2929000 USD
CY2013Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1046000 USD
CY2014Q1 us-gaap Assets
Assets
10471000 USD
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
937000 USD
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
705000 USD
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2095000 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3737000 USD
CY2014Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2248000 USD
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q1 us-gaap Redeemable Noncontrolling Interest Equity Common Carrying Amount
RedeemableNoncontrollingInterestEquityCommonCarryingAmount
0 USD
CY2013Q2 us-gaap Redeemable Noncontrolling Interest Equity Common Carrying Amount
RedeemableNoncontrollingInterestEquityCommonCarryingAmount
16882000 USD
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
70000 USD
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
39000 USD
CY2014Q1 us-gaap Treasury Stock Value
TreasuryStockValue
1252000 USD
CY2013Q2 us-gaap Treasury Stock Value
TreasuryStockValue
1252000 USD
CY2014Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
42409000 USD
CY2013Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
23580000 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36617000 USD
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31473000 USD
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-124000 USD
CY2013Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-100000 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
4486000 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
-9206000 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10471000 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11651000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18370622 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25910622 shares
CY2014Q1 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
62000 USD
CY2013Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
59000 USD
CY2014Q1 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
633000 USD
CY2013Q2 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
549000 USD
CY2014Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
257000 USD
CY2013Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
179000 USD
CY2014Q1 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
2000 USD
CY2013Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
2000 USD
CY2014Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
954000 USD
CY2013Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
789000 USD
CY2014Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
533000 USD
us-gaap Depreciation
Depreciation
153000 USD
us-gaap Depreciation
Depreciation
158000 USD
CY2013Q1 us-gaap Depreciation
Depreciation
51000 USD
CY2014Q1 us-gaap Depreciation
Depreciation
56000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1934000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1968000 USD
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
570000 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
941000 USD
CY2013Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
375000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
8850000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
65000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
26250 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
22633955 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
22633955 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
13612495 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.85
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.23
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.62
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.84
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.75
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13890205 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.00
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.00
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.85
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
csbr Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm
P9Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
89000 USD
csbr Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted
148000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2224000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2224000 USD
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2132000 USD
CY2014Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2013Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
31133333 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70103336 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38955003 shares
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66867100 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35718767 shares
CY2014Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
3236236 shares
CY2013Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
3236236 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.96
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.27
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0 USD
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3276667 shares
CY2013Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3276667 shares
CY2013 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
18600000 shares
CY2011Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
12533333 shares
CY2013Q1 csbr Common Stock Purchase Price
CommonStockPurchasePrice
0.50
CY2011Q1 csbr Common Stock Purchase Price
CommonStockPurchasePrice
0.75
CY2013Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
9300000 USD
CY2011Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
9400000 USD
us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
133000 USD
CY2013Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
500000 USD
CY2011Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
500000 USD
CY2013Q1 csbr Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
9100000 USD
csbr Percentage Of Cash Penalties
PercentageOfCashPenalties
0.010 pure
csbr Purchase Price Limit Percentage
PurchasePriceLimitPercentage
0.1 pure
CY2012 us-gaap License Costs
LicenseCosts
45000 CAD
CY2013 us-gaap Royalty Expense
RoyaltyExpense
10000 CAD
CY2013 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
3000000 USD
CY2014Q1 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
10000 CAD
CY2013Q2 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
10000 CAD
csbr Exercise Of Options To One Time Royalty Fee
ExerciseOfOptionsToOneTimeRoyaltyFee
880000 USD
CY2012Q4 csbr Exercise Of Options To One Time Royalty Fee
ExerciseOfOptionsToOneTimeRoyaltyFee
880000 USD
us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
317000 USD
us-gaap Increase Decrease In Contract Receivables Net
IncreaseDecreaseInContractReceivablesNet
277000 USD
csbr Personalized Oncology Solutions
PersonalizedOncologySolutions
1850000 USD
csbr Personalized Oncology Solutions
PersonalizedOncologySolutions
1834000 USD
CY2013Q1 csbr Personalized Oncology Solutions
PersonalizedOncologySolutions
473000 USD
CY2014Q1 csbr Personalized Oncology Solutions
PersonalizedOncologySolutions
590000 USD
csbr Translational Oncology Solutions
TranslationalOncologySolutions
4631000 USD
csbr Translational Oncology Solutions
TranslationalOncologySolutions
7258000 USD
CY2013Q1 csbr Translational Oncology Solutions
TranslationalOncologySolutions
2444000 USD
CY2014Q1 csbr Translational Oncology Solutions
TranslationalOncologySolutions
3100000 USD
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
6481000 USD
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
9092000 USD
CY2013Q1 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
2917000 USD
CY2014Q1 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
3690000 USD
csbr Cost Of Personalized Oncology Solutions
CostOfPersonalizedOncologySolutions
2030000 USD
csbr Cost Of Personalized Oncology Solutions
CostOfPersonalizedOncologySolutions
2139000 USD
CY2013Q1 csbr Cost Of Personalized Oncology Solutions
CostOfPersonalizedOncologySolutions
676000 USD
CY2014Q1 csbr Cost Of Personalized Oncology Solutions
CostOfPersonalizedOncologySolutions
614000 USD
csbr Cost Of Translational Oncology Solutions
CostOfTranslationalOncologySolutions
1740000 USD
csbr Cost Of Translational Oncology Solutions
CostOfTranslationalOncologySolutions
2585000 USD
CY2013Q1 csbr Cost Of Translational Oncology Solutions
CostOfTranslationalOncologySolutions
566000 USD
CY2014Q1 csbr Cost Of Translational Oncology Solutions
CostOfTranslationalOncologySolutions
1008000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1415000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1614000 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
592000 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
535000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2047000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2160000 USD
CY2013Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
658000 USD
CY2014Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
821000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3484000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4476000 USD
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1145000 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2120000 USD
us-gaap Operating Expenses
OperatingExpenses
10716000 USD
us-gaap Operating Expenses
OperatingExpenses
12974000 USD
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
3637000 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
5098000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4235000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3882000 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-720000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1408000 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-21000 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1202000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10769000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3132000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3558000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
164000 USD
CY2013Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-255000 USD
CY2014Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
846000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37000 USD
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000 USD
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-43000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1239000 USD
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-265000 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
839000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4278000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5121000 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-985000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-569000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000 USD
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 USD
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 USD
us-gaap Net Income Loss
NetIncomeLoss
-4284000 USD
us-gaap Net Income Loss
NetIncomeLoss
-5134000 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-990000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-574000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47294000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66860792 shares
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47737000 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66867114 shares
CY2014Q1 csbr Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
2248000 USD
CY2013Q2 csbr Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
1046000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
24000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-23000 USD
CY2013Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000 USD
CY2014Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4260000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5157000 USD
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-989000 USD
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-573000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1934000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1968000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
153000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
158000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
58000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2623000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
96000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-34000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
2000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-28000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-574000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-266000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-58000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
94000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-168000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
981000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-35000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-164000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
25000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-27000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6053000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3749000 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4716000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-01-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
CSBR
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
66867100 shares
dei Entity Registrant Name
EntityRegistrantName
CHAMPIONS ONCOLOGY, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0000771856
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
csbr Proceeds From Exercise Of Options And Warrants
ProceedsFromExerciseOfOptionsAndWarrants
0 USD
csbr Proceeds From Exercise Of Options And Warrants
ProceedsFromExerciseOfOptionsAndWarrants
USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
9195000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9195000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2011Q1 csbr Potential Milestone Payments
PotentialMilestonePayments
27000000 USD
CY2014Q1 us-gaap Deferred Revenue
DeferredRevenue
259000 USD

Files In Submission

Name View Source Status
0001144204-14-015818-index-headers.html Edgar Link pending
0001144204-14-015818-index.html Edgar Link pending
0001144204-14-015818.txt Edgar Link pending
0001144204-14-015818-xbrl.zip Edgar Link pending
csbr-20140131.xml Edgar Link completed
csbr-20140131.xsd Edgar Link pending
csbr-20140131_cal.xml Edgar Link unprocessable
csbr-20140131_def.xml Edgar Link unprocessable
csbr-20140131_lab.xml Edgar Link unprocessable
csbr-20140131_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v370638_10q.htm Edgar Link pending
v370638_ex10-1.htm Edgar Link pending
v370638_ex31-1.htm Edgar Link pending
v370638_ex31-2.htm Edgar Link pending
v370638_ex32-1.htm Edgar Link pending